Amgen settles with AbbVie over Humira biosimilar
Thousand Oaks biopharmaceutical giant Amgen announced Sept. 28 that it had reached a settlement with Chicago-based competitor AbbVie, which had sued to block Amgen’s Humira biosimilar Amjevita. The rheumatoid arthritis and inflammation treatment received U.S. Food and Drug Administration approval in September of 2016, but sales were blocked when AbbVie filed a patent infringement claim Read More →
Amgen reaffirms earnings outlook after hurricane hits Puerto Rico
After reviewing the impacts to its Puerto Rico manufacturing facility from Hurricane Maria, Thousand Oaks biotech giant Amgen reaffirmed its earnings outlook Sept. 25 and said that outreach to impacted staff was ongoing. The storm did not damage any product or in-process inventory at the plant, and the company said it did not expect any Read More →
Tri-county biotech companies targeting quality of life
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Study finds Amgen asthma drug is effective
An asthma drug being developed by Thousand Oaks-based Amgen and AstraZeneca showed significant yearly reduction for patients, according to a study published in the New England Journal of Medicine Sept. 6. Patients with severe, uncontrolled asthma using tezepelumab saw a drop in annual exacerbation compared with patients taking a placebo, Amgen said in a news Read More →
Amgen stock drops despite strong earnings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sienna stock soars after $65 million IPO
Westlake Village biotechnology company Sienna Biopharmaceuticals closed with a big gain after it raised $65 million in its initial public offering July 27. Sienna priced the 4.33 million shares it offered at $15. Shares had reached $21 around noon before ending at $19.25, a 28.3 percent premium on its opening price. The company operates in Read More →
Amgen partnering to develop new drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
